euronews.comSEP 22 min read$NVO

Weight-loss pill "Wegovy" available in German pharmacies from 1 September

Novo Nordisk's Wegovy weight-loss pill will be available in German pharmacies from 1 September, following EU approval. The prescription-only tablet, priced between 170 and 280 euros, is an alternative to the injectable version. Clinical trials showed an average weight loss of 13.6% for the tablet. The global weight-loss medicine market is projected to reach $100 billion by 2030, according to analysts.

Original reporting

euronews.com

Published Sep 2, 2026, 11:15 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Sep 2, 2026, 11:27 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Weight-loss pill "Wegovy" available in German pharmacies from 1 September — source image — Source · euronews.com

Decision brief

The 30-second read

$NVOBullishLow

Why it matters

Launch expands Novo Nordisk's obesity‑treatment portfolio and may boost European revenues.

Market read

First German availability of Wegovy tablet could influence obesity‑drug sector dynamics.

What to watch

Reimbursement negotiations and insurance coverage in Germany could limit uptake.

Relevance 7/10Novelty 7/10Timing: effective 1 September

Background

EU approved Wegovy oral tablet in July; Germany is first to sell it.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NVOBullishMedium confidence

Context

Novo Nordisk received EU approval and launched the Wegovy oral tablet in Germany, first market availability.

Expected impact

Modest upside for NVO as German sales commence.

Evidence & confidence

First European country to sell the tablet; price range €170‑€280 suggests sizable market, but rollout is limited to one market.

Market effects

Sector

Weight‑loss drug market sees new oral option, could pressure injectable competitors.

Regional

German pharma market gains a high‑price obesity treatment.

Global

Adds to $100 bn 2030 obesity‑drug market outlook.

Counterpoint

What could challenge this read

Tablet may face slower adoption due to daily dosing and side‑effects versus weekly injection.

Key entities

company
Novo Nordisk
Danish pharmaceutical company launching Wegovy oral tablet.
organization
German Diabetes Association
Provided commentary on the new treatment.

Read at source ← All news

SEP 1

$NVOHighAI 8/10

Novo Nordisk Launches Wegovy Weight-Loss Pill in Germany

Novo Nordisk has launched its Wegovy weight-loss pill in Germany, its first EU market. The pill, priced similarly to the Wegovy pen (€170-€280), competes with Eli Lilly's Foundayo. Novo claims 90% of the oral obesity market, despite Lilly's gains. The GLP-1 market is expected to exceed $100B by 2030, with pills potentially making up over a third of use.

medscape.com2 min

SEP 1

$NVOMedAI 8/10

Novo Nordiskâs AMAZE 9 Oral Obesity Trial: A New Pill in the Weight-Loss Race - TipRanks.com

Novo Nordisk (NVO) launched AMAZE 9, a Phase 3 trial for oral obesity drug zenagamtide. The study tests the pill's efficacy against placebo in adults with obesity, aiming to offer an alternative to injectable treatments. The trial is not yet recruiting, with key dates to be determined. This update highlights NVO's focus on expanding its obesity drug portfolio.

tipranks.com2 min

AUG 28

$LLYHighAI 8/10

Weight-loss drugs could transform treatment for other major health conditions. Here’s what could be next

Eli Lilly's Mounjaro and Novo Nordisk's Wegovy gained FDA approvals for expanded cardiovascular risk reduction. Studies explore semaglutide and tirzepatide for conditions like alcohol use disorder, Alzheimer's, and MASH. Novo's Rybelsus failed to slow cognitive decline in Alzheimer's trials. Lilly withdrew a heart failure application for tirzepatide.

independent.co.uk3 min

AUG 28

$NVOMed

Novo's Wegovy Pill Enters China Behind Lilly

Novo Nordisk (NYSE:NVO) submitted its oral Wegovy pill for regulatory review in China, trading at $45.88. Eli Lilly (NYSE:LLY) had previously submitted its rival pill. China's market for obesity treatments is expected to grow significantly. Novo has not disclosed approval or launch timelines. The stock trades 58.04% below its GF Value.

yahoo.com1 min

AUG 28

$LLYHighAI 8/10

FACTBOX-What other health conditions could GLP-1 weight-loss drugs treat?

The FDA approved Eli Lilly's Mounjaro for reducing heart attack/stroke risk in type 2 diabetes patients. Novo Nordisk's Wegovy gained similar approval for non-diabetic adults. Both companies' GLP-1 drugs are being tested for other conditions, including alcohol addiction, Alzheimer's, cardiovascular disease, chronic kidney disease, knee osteoarthritis, liver disease, and sleep apnea.

devdiscourse.com3 min

AUG 27

$NVOMed

Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip

Deutsche Bank downgraded Novo Nordisk (NYSE:NVO) (CSE:NOVOb) to Sell, cutting its price target by 9% to 265 Danish crowns. The move follows mixed Q2 earnings and concerns over growth, particularly for the Wegovy pill and next-gen obesity drug. Shares fell over 3% in Copenhagen trading. The bank cited high-single-digit mid-term revenue cuts and persistent growth concerns. This is the second downgrade from Deutsche Bank this year. Novo Nordisk raised its full-year profit and sales outlook but miss

investing.com2 min

Weight-loss pill "Wegovy" available in German pharmacies from 1 September